MALDI-TOF MS

MALDI-TOF MS

Matrix Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry. A high-throughput protein sequencing method based on embedding samples in a matrix from which they are desorbed by laser light.

Principle
A laser passes through the substances to be analysed, and causes them to vaporise and their molecules to fly upward into a tube. The time of flight through the tube correlates directly to mass—lighter molecules have a shorter time of flight than heavier ones. MALDI-TOF MS is a potential for measuring the mass of DNA fragments and predicting DNA sequences based on molecular mass.
References in periodicals archive ?
When we loaded the protein G eluates from the patient and controls to determine whether the IgM in the protein G eluates from the patient's serum was pentameric or monomeric, we did not detect monomeric IgM (~180-190 kDa) from patient and control protein G eluates when the gel in this molecular mass region was excised, digested with trypsin, and analyzed by MALDI-TOF MS (Fig.
The importance of MALDI-TOF MS has been recognized by a share of the 2002 Nobel Prize in Chemistry to K.
Furthermore, an additional advantage of high-throughput MALDI-TOF MS analysis is that simultaneous multiplexed genotyping can be achieved in a single experiment (16).
Several studies have reported the performance of MALDI-TOF MS for the identification of clinically relevant fungal species.
MALDI-TOF MS (Matrix-Assisted Laser Desorption Ionization) instrument for the identification of bacteria, fungi (yeasts, filamentous fungi and dermatophytes) and mycobacteria.
The Cleveland Clinic named MALDI-TOF MS as one of the "Top Ten Breakthrough Medical Technologies of 2013.
Allele specific extending probes were used for every mutant allele having different molecular weight; these amplified primers were further separated by MALDI-TOF MS.
MALDI-TOF MS was evaluated as a screen in two different ways (and each is reported separately).
MALDI-TOF MS has been routinely used since the mid-1990s and was later verified in the identification of clinical microbial isolates (7-9) 13 (28,31).
in the serum and CSF samples of the patient according to the Brucella STA kitprompted us to identify the organism using MALDI-TOF MS.
Even though the performance of MALDI-TOF MS and phenotypic systems in identifying Francisella isolates have previously been reported [11], information on the performance of the modern methods is scarce in identifying clinical isolates of Francisella species.
Due to the discordance in identification between the RapID ANA II System and MALDI-TOF MS, the bacterium was sent to the Laboratoire de Sante Publique du Quebec (LSPQ) for further characterization.